PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C

被引：0
|
作者：
Ideo, G
Giuseppe, S
Attili, A
Chirianni, A
Craxi, A
Di Perri, G
Picciotto, A
Rizzetto, M
Ruggiero, G
Suter, F
Sarracino, M
机构：
[1] Osped S Giuseppe, Dept Hepatol, Milan, Italy
[2] Univ Roma La Sapienza, Dept Gastroenterol, Rome, Italy
[3] Cotugno Hosp, Dept Infectious, Naples, Italy
[4] Univ Palermo, Dept Gastroenterol, Palermo, Italy
[5] Savoia Hosp, Dept Infect Amedeo, Turin, Italy
[6] Hepatitis Diagnosis & Therapy, Genoa, Italy
[7] Molinette Mauriziano Hosp, Dept Gastroenterol & Hepatol, I-10126 Turin, Italy
[8] Univ Naples, Dept Med & Hepatol, Naples, Italy
[9] Spedali Riumti, Dept Infect Dis, Bergamo, Italy
[10] Roche SPA, Monza, Italy
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1630
引用
收藏
页码：570A / 570A
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis
    Bruno, Savino
    Shiffman, Mitchell L.
    Roberts, Stuart K.
    Gane, Edward J.
    Messinger, Diethelm
    Hadziyannis, Stephanos J.
    Marcellin, Patrick
    HEPATOLOGY, 2010, 51 (02) : 388 - 397
  • [42] Cost-effectiveness of first-line peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in patients with mild chronic hepatitis C (cHC) in the US
    El-Serag, Hashem B.
    Patel, Kavita K.
    Wintfeld, Neil
    Green, Jesse
    Sullivan, Sean D.
    GASTROENTEROLOGY, 2006, 130 (04) : A837 - A837
  • [43] Peg-IFN alfa-2a plus ribavirin is superior compared to high dose consensus interferon (CIFN) and ribavirin in the treatment of patients with chronic hepatitis C
    Witthoeft, Thomas
    HEPATOLOGY, 2007, 46 (04) : 390A - 390A
  • [44] PHARMACOKINETICS (PK) OF RIBAVIRIN (RBV) IN PATIENTS WITH RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE (ESRD) AND CHRONIC HEPATITIS C (CHC) DURING TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) AND RBV (COPEGUS®)
    Wang, Karen
    Lawal, Adebayo A.
    Majchrowicz, Martin
    Morcos, Peter N.
    Moreira, Sebastian
    Draibe, Sergio A.
    Ghalib, Reem H.
    Zaman, Atif
    Crippin, Jeffrey S.
    Joshi, Virendra
    Martin, Paul
    Grippo, Joseph
    HEPATOLOGY, 2008, 48 (04) : 1142A - 1142A
  • [45] Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1.
    Berg, T
    von Wagner, M
    Hinrichsen, H
    Heintges, T
    Buggisch, P
    Goeser, T
    Rasenack, J
    Pape, GR
    Schmidt, WE
    Kallinowski, B
    Klinker, H
    Spengler, U
    Klapperich, B
    Popescu, M
    Zeuzem, S
    HEPATOLOGY, 2003, 38 (04) : 317A - 317A
  • [46] PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN
    Mauss, S.
    Schober, A.
    Lutz, T.
    Moog, G.
    Schuchmann, M.
    Heyne, R.
    John, C.
    Schiffelholz, W.
    Baumgarten, A.
    Hey, K. -H.
    Eisenbach, C.
    Teuber, G.
    Schmidt, W.
    Bruch, H. -R.
    Geyer, P.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S185 - S185
  • [47] Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Foster, Graham R.
    Fried, Michael W.
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Freivogel, Klaus
    Weiland, Ola
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (02) : 247 - 255
  • [48] Predictive Factors of Thrombocytopenia in Treatment of Chronic Hepatitis C (CHC) Patients With Peginterferon Alfa-2a (40KD) and Ribavirin
    Mauss, Stefan
    Schober, Andreas
    Lutz, Thomas
    Moog, Gero
    Schuchmann, Marcus
    Heyne, Renate
    John, Christine
    Schiffelholz, Willibold
    Baumgarten, Axel
    Hey, Karl-Heinz
    Eisenbach, Christoph
    Teuber, Gerlinde
    Schmidt, Wolfgang
    Bruch, Harald-Robert
    Geyer, Peter
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2011, 140 (05) : S948 - S948
  • [49] ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone
    Piratvisuth, T
    Marcellin, P
    Lau, G
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Lu, ZM
    Germanidis, G
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Button, P
    Why, RD
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 656A - 657A
  • [50] Clustering of poor prognostic factors in heavier patients with chronic hepatitis C (CHC):: Baseline characteristics and outcomes with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (RBV, COPEGUS®) in randomized, international, Phase III trials
    Swain, MG
    Foster, G
    Hadziyannis, S
    Heathcote, J
    Jensen, D
    Lee, S
    Pockros, P
    Sulkowski, M
    Trepo, C
    HEPATOLOGY, 2005, 42 (04) : 687A - 688A
12345